A 2024 meta-analysis by Xu et al. demonstrated that PD-L1 positivity (≥1%) in nasopharyngeal carcinoma correlates with improved response rates and progression-free survival under anti-PD-1/PD-L1 therapy. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.